Brand-name drug companies fail to meet R&D commitments

Kondro, Wayne
August 2006
CMAJ: Canadian Medical Association Journal;8/15/2006, Vol. 175 Issue 4, p344
Academic Journal
The article discusses the failure by brand-name drug companies to meet the research and development (R&D) commitments in Canada. A report by the Patented Medicine Prices Review Board (PMPRB) shows an increase in spending on brand-name drugs by Canadians, but relatively low company outlays for research and development. It is suggested that the shortfall is due to lack of federal intellectual property law. An aggressive and innovative commercial environment is suggested as a corrective measure.


Related Articles

  • Brand-name drug companies continue to break research and development spending promise. Vogel, Lauren // CMAJ: Canadian Medical Association Journal;8/10/2010, Vol. 182 Issue 11, pE519 

    The article presents the result of the annual report of the Patented Medicine Prices Review Board that indicates the continued failure of brand-name drug companies in Canada in fulfilling its promise regarding research and development spending. It states that Canadians are still paying the...

  • Canada's Pharmaceutical Price Control Paradox. Brett J. Skinner // Fraser Forum;Jun2005, p12 

    Presents a question and answer advisory about the practices of the drug price control in Canada. Role of the Patented Medicines Prices Review Board in enforcing drug price regulations; Applicability of federal drug price regulations to the legal class of drugs known as patented drugs; Influence...

  • A high price to pay for generic drugs in Canada.  // PharmacoEconomics & Outcomes News;8/12/2006, Issue 509, p11 

    The article focuses on the high price of generic drugs in Canada in 2005 compared to other countries, according to a report from the Canadian Patented Medicines Prices Review Board. Using market exchange rates, the report, based on data from IMS Health, compared prices for generics, non-patented...

  • Drugmakers' research habit.  // Dow Theory Forecasts;10/22/2012, Vol. 68 Issue 43, p4 

    The article focuses on a research related to the development of pharmaceutical industry in the U.S. It mentions that the expiry of patent and declining research productivity helps in improving drug stocks. It states that when the patent expires, cheaper generics get into the market that undercut...

  • Pharmaceutical patent challenges--time for reassessment? Glass, Gregory // Nature Reviews Drug Discovery;Dec2004, Vol. 3 Issue 12, p1057 

    For nearly 15 years after the passage of the Hatch-Waxman Act in 1984, generics drug companies took little advantage of its provisions, which provided financial incentives to them for challenging the patents of branded pharmaceutical products. However, during the past 3-5 years, generics...

  • Competition, Market Power, and Pricing in Brand Name Pharmaceutical Markets. Hay, Joel W. // Harvard Health Policy Review;Spring2013, Vol. 14 Issue 1, p8 

    Branded pharmaceutical innovation has been declining substantially for over 60 years. Drug innovation is dependent on sufficiently high prices and profits to reward risky and costly R&D. In assessing competition in pharmaceutical markets government agencies evaluating potentially...

  • Are settlements of patent disputes illegal per se? Blair, Roger D.; Cotter, Thomas F. // Antitrust Bulletin;Summer/Fall2002, Vol. 47 Issue 2/3, p491 

    Focuses on the law suits filed by the brand name drug manufacturers against the producers of generic drugs for patent infringement. Legality of some settlements of patent judicial determination; Suitability of per se treatment in the pharmaceutical cases; Role of the patent systems.

  • What happens when a patent expires. O'Connor, Kerry // GP: General Practitioner;12/7/2007, p46 

    The article presents suggestions on how to deal in a situation when the patent of any drug expires. As stated, the life of the patent for a branded drug starts as soon as the patent is filed. It is suggested that, a patent can be lengthened by introducing a new formulation for the brand, or...

  • Issues of the Legal Protection of Brand-Name Drugs in the European Union. Kukrus, Ants; Kartus, Raul // Baltic Journal of European Studies;Sep2011, Vol. 1 Issue 2, p192 

    The manufacturing of pharmaceutical products is divided between two main groups of manufacturers-the ones manufacturing so- called brand-name drugs or original drugs, i.e. new research-based drugs protected by patent, and the ones manufacturing old traditional drugs or generic drugs after the...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics